🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Clinical Evaluation of With or Without Internal Limiting Membrane Peeling for Idiopathic Epiretinal Membrane Surgery: A Randomized Controlled Trial

RecruitingNAAges 18 Years - anyAllSecond Affiliated Hospital, Zhejiang University, …
NCT07142785 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Idiopathic epiretinal membrane (ERM) is an age-related degenerative retinal condition. One of the primary treatment approaches is vitrectomy combined with epiretinal membrane peeling. However, whether to concurrently perform internal limiting membrane (ILM) peeling remains clinically controversial. Therefore, this study aims to compare the efficacy and safety of performing versus omitting ILM peeling during idiopathic ERM surgery.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients aged \>18 years presenting to our hospital within the study period. * Patients diagnosed with idiopathic epiretinal membrane (ERM) based on examination. * Patients with best-corrected visual acuity (BCVA) ≤ 0.6 or the presence of metamorphopsia. Exclusion Criteria: * Patients with secondary ERM identified during preoperative evaluation (e.g., secondary to retinal vein occlusion). * Patients with concomitant ocular diseases affecting the macula, such as macular degeneration, macular schisis, or macular atrophy. * Patients with a history of ocular trauma or previous ocular surgery (except for cataract surgery). * Patients with severe systemic diseases contraindicated for surgery. * Patients with poor compliance or concomitant psychiatric disorders. * Patients who participated in other clinical trials during the follow-up period or who were lost to follow-up.
💊

What it tests

  • Epiretinal membrane peeling
  • Epiretinal membrane peeling combined with internal limiting membrane peeling
📍

Where

1 site
Eye Center of the Second Affiliated Hospital of Zhejiang University
Hangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy